Lilly Asia Ventures

Enchannel Medical is a global innovation platform specializing in the treatment of atrial fibrillation through advanced electrophysiology solutions. The company offers a comprehensive treatment approach that combines three-dimensional mapping with pulsed field ablation (PFA) technology. Enchannel has developed a four-dimensional mapping system that integrates both magnetoelectric positioning contact and non-contact mapping technologies. This system enables real-time visualization of arrhythmia mechanisms during electrophysiological surgeries, facilitating safer and more efficient cardiac procedures for physicians. By focusing on innovative mapping and ablation techniques, Enchannel aims to enhance the efficacy of atrial fibrillation treatments.

Heyuan Medical Devices serves as an enterprise service provider, offering specialized medical equipment and support solutions tailored to the needs of healthcare institutions and organizations

Rona Therapeutics is an RNA therapeutics platform focused on the discovery, development, and commercialization of innovative RNA medicines. The company specializes in modular and programmable RNA therapies, offering services that encompass oligonucleotide therapies, RNA editing, and polymeric molecules. Rona Therapeutics aims to create transformative RNA treatments that can significantly alter disease management across various therapeutic areas. To achieve this, the company is developing advanced facilities to enhance nucleic acid synthesis, delivery systems, oligonucleotide chemical modification, and RNA biology. By fostering an environment that promotes innovation, Rona Therapeutics is dedicated to improving patient outcomes and supporting healthier, longer lives.

Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.

Stairway Medical is a ladder of human progress and evolution stairs up for human health. The technology and products will be applicable to medical scenarios such as human function restoration, disease treatment, and functional enhancement, as well as related scientific research work.

Fine Vision is a company with R&D facilities in Nanjing and Wuhan that focuses on femtosecond laser application research in the fields of ocular surgery and biomaterial processing. The entire femtosecond laser corneal refractive surgery equipment, its first commercially available item, was developed by the university's Wuhan Optoelectronics National Research Center under the Huazhong Technology Technology transition.

Verdiva Bio is a company creating cutting-edge treatments that improve results for patients with obesity, cardiometabolic diseases, and associated problems by making treatment options more patient-friendly. Verdiva Bio operates in the cardiometabolic health sector, creating innovative treatments designed to improve the quality of care for patients facing these health issues.

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company that develops and commercializes revolutionary medicines for autoimmune illnesses. The company utilizes its team's experience in drug development to secure top-tier assets focused on promising targets, and implementing them in disease areas with considerable unmet needs.

Syneron was founded by Sinovation Ventures and is dedicated to using artificial intelligence and biotechnology to address two significant global challenges: the efficient development of novel biological therapies and the low-carbon manufacture of biochemicals.

Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

Chimagen Biosciences is focused on developing a novel class of multi-functional monoclonal antibodies specifically for cancer therapy. The company engages in the discovery and development of these therapeutic antibodies and conducts clinical studies to evaluate their effectiveness. By aiming to address unmet medical needs in oncology, Chimagen Biosciences seeks to deliver innovative treatment options for patients battling cancer.

XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Rona Therapeutics is an RNA therapeutics platform focused on the discovery, development, and commercialization of innovative RNA medicines. The company specializes in modular and programmable RNA therapies, offering services that encompass oligonucleotide therapies, RNA editing, and polymeric molecules. Rona Therapeutics aims to create transformative RNA treatments that can significantly alter disease management across various therapeutic areas. To achieve this, the company is developing advanced facilities to enhance nucleic acid synthesis, delivery systems, oligonucleotide chemical modification, and RNA biology. By fostering an environment that promotes innovation, Rona Therapeutics is dedicated to improving patient outcomes and supporting healthier, longer lives.

Pyrotech pharmaceuticals is a biotechnology company that focuses om development for drugs for the treatment of inflammation and tumors.

Healingovation is a med-tech company that specializes in the development and manufacturing of surgical robots, intelligent diagnosis and treatment equipment.

IMPACT Therapeutics, Inc. is a biotechnology company based in Shanghai, China, focused on discovering, developing, and commercializing innovative therapeutics for cancer and other life-threatening diseases. Founded in 2009, the company is dedicated to creating targeted anti-cancer treatments that leverage the concept of synthetic lethality. Its research and development efforts include a variety of novel drug projects, such as PARP inhibitors, Wee1 inhibitors, and agents targeting the Hedgehog pathway, among other DNA damage response (DDR) agents. Through its commitment to advancing targeted therapies, IMPACT Therapeutics aims to provide patients with new, effective treatment options for challenging medical conditions.

Alumis is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for autoimmune disorders. By leveraging a proprietary data analytics platform and biological insights, Alumis aims to transform the treatment landscape for patients suffering from these conditions. The company focuses on identifying and advancing therapeutics based on genetically validated targets, which enables the creation of targeted therapies that significantly improve patient outcomes. With a team of experts experienced in drug discovery and immunology, Alumis seeks to replace broad immunosuppression with more effective, targeted treatment options, ultimately enhancing the quality of life for individuals affected by autoimmune diseases.

Beijing Targeting One Technology Co., Ltd. specializes in the development and production of biomedical instruments and consumables, focusing on in vitro diagnostic reagents for precision medicine, health management, and life science research. Established in 2015 and based in Beijing, the company offers a range of products including sample preparation apparatus, biochip readers, digital PCR supplies, and genetic testing kits. Its digital PCR solutions play a crucial role in medical diagnostics, with applications in transplant rejection monitoring, targeted sequencing, tumor liquid biopsy, and non-invasive prenatal screening. Targeting One aims to enhance gene testing and precision medicine through its innovative technologies and comprehensive offerings.

Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.

Synnovation Therapeutics is a precision oncology company dedicated to developing small molecule therapies that target key mechanisms driving cancer. By leveraging expertise in medicinal chemistry, cancer biology, and patient-focused precision medicine, the company aims to create a diverse pipeline of innovative targeted therapies. Its focus on highly validated disease targets allows healthcare providers to address limitations in current treatment standards, ultimately striving to enhance patient outcomes and transform cancer care. Synnovation Therapeutics is committed to advancing these therapies efficiently into clinical trials, with the goal of improving the lives of individuals affected by cancer.

Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition.

Akura Medical is focused on developing innovative medical devices aimed at improving the process of thrombectomy, specifically through a next-generation device designed for easy use in a single-pass procedure to efficiently remove blood clots. The company specializes in thrombectomy devices and also offers a range of surgical, medical, dental, and veterinary instruments. By providing effective solutions for clot removal, Akura Medical enables healthcare professionals to better address critical needs and treat venous thromboembolism of varying sizes.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Ronovo Surgical is an emerging medtech company dedicated to advancing minimally invasive surgery (MIS) through innovative robotic technology. The company has developed a soft tissue surgery robot platform that utilizes next-generation robotics and advanced digital solutions to enhance surgical precision and efficiency. By focusing on various surgical specialties, Ronovo aims to optimize patient outcomes and improve health economics, particularly within the Chinese medical industry. Their efforts are designed to transform surgical care by delivering more effective and less invasive surgical options.

Pixin Technology is a provider of decision-making products for medical imaging using artificial intelligence.

Leadsynbio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzyme engineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.

Enchannel Medical is a global innovation platform specializing in the treatment of atrial fibrillation through advanced electrophysiology solutions. The company offers a comprehensive treatment approach that combines three-dimensional mapping with pulsed field ablation (PFA) technology. Enchannel has developed a four-dimensional mapping system that integrates both magnetoelectric positioning contact and non-contact mapping technologies. This system enables real-time visualization of arrhythmia mechanisms during electrophysiological surgeries, facilitating safer and more efficient cardiac procedures for physicians. By focusing on innovative mapping and ablation techniques, Enchannel aims to enhance the efficacy of atrial fibrillation treatments.

Pyrotech pharmaceuticals is a biotechnology company that focuses om development for drugs for the treatment of inflammation and tumors.

Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.

Novlead Biotech is a developer and manufacturer of medical devices specializing in cardiopulmonary, respiratory, and anti-infection applications. The company leverages technological innovations, particularly the medical application of nitric oxide, to address conditions such as pulmonary hypertension and infectious diseases. By focusing on these critical areas, Novlead Biotech aims to enhance treatment efficiency in hospitals and improve the quality of life for patients. Through its advancements, the company contributes to safer and healthier outcomes in healthcare.

Langlai Technology is a clinical-stage innovative drug research and development company. Adhering to the dual-drive strategy of synchronously improving the R&D pipeline and platform construction, it has built a full-process new drug R&D process from concept verification, candidate compound screening, preclinical druggability development to clinical research. system.

Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.

Alebund Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for renal diseases and related chronic conditions. The company specializes in the research, development, regulatory approval, and commercialization of medicines aimed at treating various kidney diseases, including chronic kidney disease, complications associated with dialysis, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified and balanced pipeline of drug candidates, Alebund Pharmaceuticals aims to provide comprehensive and high-quality solutions for patients suffering from renal diseases.

Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.

ArriVent Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative treatments for currently untreatable cancers. The company is committed to addressing unmet medical needs in oncology by leveraging its team's extensive drug development experience. ArriVent aims to maximize the potential of its lead candidate, furmonertinib, while advancing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. With an initial emphasis on solid tumors, ArriVent seeks to bring differentiated medicines from development through to commercialization, ultimately improving patient outcomes in cancer treatment.

Ronovo Surgical is an emerging medtech company dedicated to advancing minimally invasive surgery (MIS) through innovative robotic technology. The company has developed a soft tissue surgery robot platform that utilizes next-generation robotics and advanced digital solutions to enhance surgical precision and efficiency. By focusing on various surgical specialties, Ronovo aims to optimize patient outcomes and improve health economics, particularly within the Chinese medical industry. Their efforts are designed to transform surgical care by delivering more effective and less invasive surgical options.

LavaMed is a China-based manufacturer of medical devices specializing in neuro-interventional solutions for ischemic and hemorrhagic strokes, as well as other cerebrovascular diseases. The company develops a range of devices that address issues related to hemorrhage and ischemia, along with associated accessories. These products are utilized in neurovascular minimal interventional therapy, aiming to enhance clinical treatment outcomes. By focusing on innovative solutions, LavaMed supports healthcare enterprises in improving both their production processes and quality standards in the medical field.

Rgenta Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of RNA-targeting medicines with a primary focus on oncology and neurological disorders. Founded in 2018, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This platform enables the design of small-molecule compounds that modulate interactions among the spliceosome, regulatory proteins, and RNAs. By unlocking the therapeutic potential of previously undruggable targets, Rgenta aims to create oral, small-molecule therapies that address critical needs in human disease treatment, particularly in the realm of cancer.

Lupeng Pharmaceutical is a clinical-stage company dedicated to the discovery and development of innovative therapies for cancer and other serious health conditions. The company specializes in researching and developing novel molecular drugs aimed at treating various diseases, including tumors and hepatitis B. By focusing on innovative drug development, Lupeng Pharmaceutical aims to provide effective treatment options for patients suffering from these challenging health issues.

Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.

Neukio Biotherapeutics specializes in developing allogenic immune cell therapies for cancer treatment. The company is dedicated to the research, development, and industrialization of immune cell drugs, particularly through its innovative iPSC-CAR-NK technology. By combining in-house innovation with collaborations with leading partners, Neukio aims to create effective therapeutic solutions for cancer patients globally. Through its efforts, the company seeks to advance the commercialization of these novel treatments, ensuring they are accessible to oncology providers and ultimately improving patient outcomes.

GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

ClinChoice Kunling was established in Tianjin inSince its establishment, through its own organic growth and strategic mergers and acquisitions, ClinChoice has more than 3,000 clinical R&D professionals around the world, located in hot cities and regions of domestic and foreign pharmaceutical R&D, and has developed into a local clinical CRO enterprise model supporting innovative drug device R&D. . The company adheres to the connotation of "Kunxing Zhiyuan · Ling creates the future", which means to become an ideal partner for the clinical research and development of innovative pharmaceutical devices.

ProfoundBio is a clinical-stage biotechnology company dedicated to creating innovative antibody-based therapeutics aimed at treating cancer. Utilizing proprietary technology platforms, the company has developed a diverse pipeline of antibody-drug conjugate (ADC) candidates targeting both solid tumors and hematological malignancies. These drug candidates are currently in various stages of discovery, preclinical, and clinical development. ProfoundBio's focus is on harnessing the immune system to provide patients with more effective treatments that have the potential for curative outcomes.

Rona Therapeutics is an RNA therapeutics platform focused on the discovery, development, and commercialization of innovative RNA medicines. The company specializes in modular and programmable RNA therapies, offering services that encompass oligonucleotide therapies, RNA editing, and polymeric molecules. Rona Therapeutics aims to create transformative RNA treatments that can significantly alter disease management across various therapeutic areas. To achieve this, the company is developing advanced facilities to enhance nucleic acid synthesis, delivery systems, oligonucleotide chemical modification, and RNA biology. By fostering an environment that promotes innovation, Rona Therapeutics is dedicated to improving patient outcomes and supporting healthier, longer lives.

IMPACT Therapeutics, Inc. is a biotechnology company based in Shanghai, China, focused on discovering, developing, and commercializing innovative therapeutics for cancer and other life-threatening diseases. Founded in 2009, the company is dedicated to creating targeted anti-cancer treatments that leverage the concept of synthetic lethality. Its research and development efforts include a variety of novel drug projects, such as PARP inhibitors, Wee1 inhibitors, and agents targeting the Hedgehog pathway, among other DNA damage response (DDR) agents. Through its commitment to advancing targeted therapies, IMPACT Therapeutics aims to provide patients with new, effective treatment options for challenging medical conditions.

GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

ArriVent Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative treatments for currently untreatable cancers. The company is committed to addressing unmet medical needs in oncology by leveraging its team's extensive drug development experience. ArriVent aims to maximize the potential of its lead candidate, furmonertinib, while advancing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. With an initial emphasis on solid tumors, ArriVent seeks to bring differentiated medicines from development through to commercialization, ultimately improving patient outcomes in cancer treatment.

Leadsynbio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzyme engineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.

Virtue Diagnostics (Suzhou) Co., Ltd. is an in vitro diagnostic company established in 2019 and headquartered in Suzhou, China, with a research and development office in Singapore. The company specializes in developing advanced diagnostic technologies aimed at infectious diseases, cancer, and chronic diseases. Its offerings include clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. Through these technologies, Virtue Diagnostics aims to enhance disease detection and management, contributing to improved healthcare outcomes.

ImmuneOnco Biopharma, established in June 2015 in Zhangjiang High-Tech Park, Shanghai, is an early-stage biopharmaceutical company focused on developing innovative cancer immunotherapy products. The company aims to combat cancer by reversing immune suppression caused by cancer cells and actively targeting their eradication. ImmuneOnco employs a systematic approach to leverage both the innate and adaptive immune systems, which positions it among the few biotechnology firms globally pursuing this strategy. The company has developed a diverse pipeline of 14 drug candidates, with eight currently undergoing clinical programs. This extensive portfolio underscores ImmuneOnco's deep understanding of cancer biology and immunology, as well as its capability to translate scientific research into viable therapeutic options.

Transcenta Holding Ltd. is a clinical-stage biotherapeutics company focused on the research, development, and manufacturing of antibody-based therapeutics. Established in 2019 and headquartered in Suzhou, China, the company operates additional facilities in Shanghai, Hangzhou, Beijing, Waltham, and Princeton. Transcenta's integrated approach encompasses the discovery and development of innovative antibodies aimed at addressing various medical conditions, particularly in oncology and specific non-oncology areas such as bone and kidney disorders. The company is currently advancing nine therapeutic antibody molecules through clinical development, underscoring its commitment to improving patient outcomes. Transcenta was formed through the merger of HJB and MabSpace Biosciences, positioning it as a significant player in the global biopharmaceutical landscape.

Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.

Novlead Biotech is a developer and manufacturer of medical devices specializing in cardiopulmonary, respiratory, and anti-infection applications. The company leverages technological innovations, particularly the medical application of nitric oxide, to address conditions such as pulmonary hypertension and infectious diseases. By focusing on these critical areas, Novlead Biotech aims to enhance treatment efficiency in hospitals and improve the quality of life for patients. Through its advancements, the company contributes to safer and healthier outcomes in healthcare.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Tripod Preclinical Research is a Contract Research Organization that specializes in providing preclinical research services to the biopharmaceutical and medical device industries. The company offers a comprehensive range of services, including drug safety evaluation for new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Tripod's expertise encompasses non-human primate disease models, pharmacological efficacy studies, early drug evaluation, and Good Laboratory Practices (GLP) toxicology. Additionally, the organization supports translational medicine and clinical trials, along with biological analysis and the management of biological sample banks. By delivering these services, Tripod aids drug developers and researchers in advancing their projects through the critical early stages of research and development.

Hopstem Biotechnology LLC is a Houston-based company that focuses on the development of neural stem cell technology and stem cell therapies specifically for neurological disorders. Established in 2019, the company specializes in the neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). By leveraging its advanced technologies, Hopstem aims to enhance biomedical research and improve diagnostic and therapeutic options for various neurological conditions. Through its innovative approaches, the company seeks to provide effective treatment solutions for patients suffering from these disorders.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, established in 2018. The company is dedicated to developing clinical candidates targeting cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at treating resistant hypertension and primary aldosteronism. CinCor Pharma's mission is to advance its promising clinical candidates toward marketing approval, emphasizing the development of innovative therapies for patients suffering from cardio-renal conditions.

OriGynMED provides deep professional resources for the invested companies through its global ecosystem to help the business development of the companies. It is a technology-based medical company.

ForQaly specializes in the development of minimally invasive ventricular assist devices designed to treat heart failure patients. The company focuses on creating therapeutic devices that enhance circulation while ensuring affordability for patients. Their products are characterized by features such as reduced trauma, high auxiliary flow, and user-friendly design, providing healthcare professionals with effective solutions for improving patient health. By combining innovation with accessibility, ForQaly aims to address the clinical needs of patients suffering from heart conditions.

Alebund Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for renal diseases and related chronic conditions. The company specializes in the research, development, regulatory approval, and commercialization of medicines aimed at treating various kidney diseases, including chronic kidney disease, complications associated with dialysis, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified and balanced pipeline of drug candidates, Alebund Pharmaceuticals aims to provide comprehensive and high-quality solutions for patients suffering from renal diseases.

XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Ionova Life Science Co., Ltd. is a biotechnology company based in Shenzhen, China, with additional offices in Hong Kong, Macao, and the Greater Bay Area. Founded in 2016, the company focuses on the discovery and development of novel medicines for cancer treatment, specializing in oncology, immuno-oncology, and tumor-targeted therapies. Ionova employs an in-house built discovery platform to facilitate the development of innovative anti-tumor drugs and immunomodulatory agents. Through its research efforts, the company aims to advance treatments that specifically target tumors and enhance the immune response against cancer.

Abogen Biosciences, established in 2019 and headquartered in Jiangsu, China, specializes in the development of nucleic acid-based therapeutics, including RNA and DNA treatments, for combating cancer and infectious diseases.

MediTrust Health is a leading healthcare platform in China that offers a wide range of health insurance products and comprehensive medical services. The company connects pharmaceutical companies, insurers, hospitals, and patients, creating a cohesive ecosystem that benefits all stakeholders involved. By integrating high-quality medical resources with health insurance, MediTrust Health aims to deliver affordable, personalized healthcare solutions to families. In addition to its insurance offerings, the company focuses on improving the management of medical expenses and enhancing patient access to necessary services through innovative payment solutions. MediTrust Health's commitment to addressing the complexities of medical financing and providing diverse healthcare benefits positions it as a significant player in the healthcare industry.

Scivita Medical is a technology-focused enterprise specializing in optical diagnosis and treatment, as well as the development of multidimensional imaging and high-performance materials for minimally invasive medical procedures. The company offers a range of products, including flexible and rigid endoscopes, designed to enhance the capabilities of medical professionals. Its product lineup features advanced technologies such as ultra-high-definition visualization, 3D imaging, and fluorescence visualization, which facilitate precise diagnostics and treatments. Key offerings include a 4K medical endoscope camera system, integrated 4K-3D endoscope systems, and various single-use endoscopic devices for applications in gynecology, urology, and pulmonology. Scivita Medical aims to provide doctors with innovative tools that improve patient outcomes through enhanced visualization and minimally invasive techniques.

Zentera Therapeutics is a biopharmaceutical company.

Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.

Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.

Neukio Biotherapeutics specializes in developing allogenic immune cell therapies for cancer treatment. The company is dedicated to the research, development, and industrialization of immune cell drugs, particularly through its innovative iPSC-CAR-NK technology. By combining in-house innovation with collaborations with leading partners, Neukio aims to create effective therapeutic solutions for cancer patients globally. Through its efforts, the company seeks to advance the commercialization of these novel treatments, ensuring they are accessible to oncology providers and ultimately improving patient outcomes.

Lupeng Pharmaceutical is a clinical-stage company dedicated to the discovery and development of innovative therapies for cancer and other serious health conditions. The company specializes in researching and developing novel molecular drugs aimed at treating various diseases, including tumors and hepatitis B. By focusing on innovative drug development, Lupeng Pharmaceutical aims to provide effective treatment options for patients suffering from these challenging health issues.

ProfoundBio is a clinical-stage biotechnology company dedicated to creating innovative antibody-based therapeutics aimed at treating cancer. Utilizing proprietary technology platforms, the company has developed a diverse pipeline of antibody-drug conjugate (ADC) candidates targeting both solid tumors and hematological malignancies. These drug candidates are currently in various stages of discovery, preclinical, and clinical development. ProfoundBio's focus is on harnessing the immune system to provide patients with more effective treatments that have the potential for curative outcomes.

ArriVent Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative treatments for currently untreatable cancers. The company is committed to addressing unmet medical needs in oncology by leveraging its team's extensive drug development experience. ArriVent aims to maximize the potential of its lead candidate, furmonertinib, while advancing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. With an initial emphasis on solid tumors, ArriVent seeks to bring differentiated medicines from development through to commercialization, ultimately improving patient outcomes in cancer treatment.

Insilico is a company that specializes in the development of new materials and system construction, utilizing a methodology that emphasizes efficiency and cost-effectiveness through the convergence of information technology and materials science. The company offers a range of consultancy services focused on product and material development, including molecular modeling and simulation, as well as regulatory compliance and quality control. Additionally, Insilico provides solutions for managing manufacturing and production information, aiming to enhance the product development process for its clients.

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

Synthekine Inc. is a biotechnology company focused on developing innovative cytokine therapies and immunotherapies for cancer and autoimmune disorders. Established in 2018 and located in Menlo Park, California, the company employs advanced platforms such as engineered partial agonists and orthogonal cell therapies. Its Synthekine Platform utilizes surrogate agonists instead of traditional mutant cytokines, allowing for the creation of therapeutics that enhance efficacy while minimizing side effects. The product pipeline includes STK-009, an orthogonal ligand, and SYNCAR-001, a CAR-T therapy targeting CD-19, along with STK-012, which consists of partial agonists of IL-2. Synthekine aims to revolutionize treatment paradigms by harnessing the principles of cytokine partial agonism and immunological specificity, leading to novel immunotherapies that improve patient outcomes.

Rgenta Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of RNA-targeting medicines with a primary focus on oncology and neurological disorders. Founded in 2018, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This platform enables the design of small-molecule compounds that modulate interactions among the spliceosome, regulatory proteins, and RNAs. By unlocking the therapeutic potential of previously undruggable targets, Rgenta aims to create oral, small-molecule therapies that address critical needs in human disease treatment, particularly in the realm of cancer.

Duality Biologics, founded in January 2020 by Dr. John Zhu, is a biotechnology company focused on developing innovative therapies for oncology and autoimmune diseases. The company is dedicated to addressing unmet medical needs through its internal pipeline, which includes nearly ten promising bispecific antibodies and Antibody-Drug Conjugate (ADC) candidates, several of which are in the investigational new drug (IND) stage. Duality Bio has established a next-generation ADC platform, backed by global intellectual property rights, to enhance drug development. The efficacy of this platform is demonstrated by multiple drug candidates currently under development, aimed at improving treatment outcomes for patients suffering from cancer and autoimmune disorders.

Elpiscience Biopharmaceuticals Co., Ltd. is a clinical-stage immunology company based in Pudong, China, with an additional office in Suzhou. The company specializes in developing next-generation immunotherapies for cancer treatment, focusing on a diverse pipeline of innovative molecules that target various areas within immuno-oncology. Founded by experienced leaders and scientists in the biopharmaceutical industry, Elpiscience aims to advance at least one new therapeutic candidate into clinical trials each year, striving to enhance treatment options for cancer patients globally.

Alebund Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for renal diseases and related chronic conditions. The company specializes in the research, development, regulatory approval, and commercialization of medicines aimed at treating various kidney diseases, including chronic kidney disease, complications associated with dialysis, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified and balanced pipeline of drug candidates, Alebund Pharmaceuticals aims to provide comprehensive and high-quality solutions for patients suffering from renal diseases.

Scivita Medical is a technology-focused enterprise specializing in optical diagnosis and treatment, as well as the development of multidimensional imaging and high-performance materials for minimally invasive medical procedures. The company offers a range of products, including flexible and rigid endoscopes, designed to enhance the capabilities of medical professionals. Its product lineup features advanced technologies such as ultra-high-definition visualization, 3D imaging, and fluorescence visualization, which facilitate precise diagnostics and treatments. Key offerings include a 4K medical endoscope camera system, integrated 4K-3D endoscope systems, and various single-use endoscopic devices for applications in gynecology, urology, and pulmonology. Scivita Medical aims to provide doctors with innovative tools that improve patient outcomes through enhanced visualization and minimally invasive techniques.

Ronovo Surgical is an emerging medtech company dedicated to advancing minimally invasive surgery (MIS) through innovative robotic technology. The company has developed a soft tissue surgery robot platform that utilizes next-generation robotics and advanced digital solutions to enhance surgical precision and efficiency. By focusing on various surgical specialties, Ronovo aims to optimize patient outcomes and improve health economics, particularly within the Chinese medical industry. Their efforts are designed to transform surgical care by delivering more effective and less invasive surgical options.

EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.

Nucleix Ltd. is a company that develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on identifying subtle changes in DNA methylation patterns to enhance cancer detection. The company's key products include Bladder EpiCheck, a urine test designed for monitoring bladder cancer, and Lung EpiCheck, a blood test aimed at the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix enables healthcare providers to improve treatment outcomes through more accurate cancer screening and monitoring. The company has established distribution partnerships in several countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology, dedicated to developing innovative antibody-drug conjugate therapies targeting CD46. The company focuses on treating late-stage multiple myeloma and prostate cancer, among other indications. Its platform is designed to advance therapies for both adenocarcinoma and neuroendocrine cancers, providing healthcare professionals with effective treatment options for patients facing these advanced stages of cancer.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on xenotransplantation. The company aims to address the critical shortage of organ donors by utilizing advanced gene editing techniques to develop safe and effective cells, tissues, and organs for human transplantation. Their mission is to eliminate the waiting period associated with organ transplants, providing patients with access to life-saving organs. By harnessing cutting-edge genetic editing technology, Qihan Biotech seeks to create viable organs that can be transplanted into humans, thereby contributing to a solution for the global organ donor crisis.

Sichuan Kelun Pharmaceutical Co., Ltd. is a pharmaceutical company based in Chengdu, China, established in 1996. The company specializes in the research, development, manufacturing, distribution, and sale of a wide range of pharmaceutical products both in China and internationally. Its primary focus is on injection products, including glucose and sodium chloride injections, as well as high-volume and small-volume infusions, sterile powder injections, and various other dosage forms such as tablets, capsules, and oral liquids. Additionally, Sichuan Kelun produces medical packaging materials and medical instruments, catering to diverse healthcare needs. As a subsidiary of Sichuan Kelun Industry Group, the company plays a significant role in the pharmaceutical sector.

NovoCodex is involved in the research, development, and manufacture of biological products. Its mission is to provide cutting-edge technology to meet clinical needs. In Binhai New City Science and Technology Park, the company has established a biopharmaceutical laboratory with experience and capabilities in genetic engineering construction, cell culture, toxin synthesis, ADC coupling, preparation filling, preclinical research, and clinical research.

FutureGen is a biopharmaceutical company focused on developing innovative biologics in the fields of immunology and cancer. The company utilizes its advanced Structure-based Targeted Evolution Platform (STEP) to efficiently screen and produce high-quality antibodies aimed at discovering new drug treatments. By integrating various technologies, FutureGen aims to enhance the development of antibody drugs that provide improved therapies for cancer and related diseases. The company possesses expertise in medication development, clinical research, and quality control, positioning it to make significant contributions to the biopharmaceutical industry and improve patient outcomes.

Regor Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting oncology, metabolic diseases, and autoimmune diseases. Utilizing its proprietary CARD (Computer Accelerated Rational Discovery) platform, Regor integrates various scientific disciplines, including structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development. This approach allows the company to efficiently produce both best-in-class and first-in-class therapeutic molecules. With a strong emphasis on scientific expertise, Regor Therapeutics aims to deliver clinically differentiated treatments that address unmet medical needs.

Beijing Targeting One Technology Co., Ltd. specializes in the development and production of biomedical instruments and consumables, focusing on in vitro diagnostic reagents for precision medicine, health management, and life science research. Established in 2015 and based in Beijing, the company offers a range of products including sample preparation apparatus, biochip readers, digital PCR supplies, and genetic testing kits. Its digital PCR solutions play a crucial role in medical diagnostics, with applications in transplant rejection monitoring, targeted sequencing, tumor liquid biopsy, and non-invasive prenatal screening. Targeting One aims to enhance gene testing and precision medicine through its innovative technologies and comprehensive offerings.

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.